Keywords
mature cystic teratoma, endometriosis, concomitant diseases
Posted Date: January 28th, 2020
DOI: https://doi.org/10.21203/rs.2.21971/v1
License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Version of Record: A version of this preprint was published at Journal of Gynecology Obstetrics and
Human Reproduction on November 1st, 2020. See the published version at
https://doi.org/10.1016/j.jogoh.2020.101786.
Page 2/18
Abstract
Background
We investigated the incidence of endometriosis in women with mature cystic ovarian teratoma and
analyzed the clinicopathologic features of this occurrence.
Methods
From January 2017 through December 2018, we retrospectively studied 71 women who had undergone
cystectomy for mature cystic ovarian teratoma (n = 55, teratoma group) and coexistence of
endometriosis and mature cystic ovarian teratoma (n = 16, complex group). Serum anti-Müllerian
hormone (AMH) levels were measured preoperatively and one month after surgery.
Results
Sixteen (22.54%) patients had coexistence of endometriosis and mature cystic ovarian teratoma
(complex group); 55 patients had mature cystic teratoma alone (teratoma group). Early-stage
endometriosis (stage I) was present in eight patients and advanced-stage endometriosis (stage III or IV)
was present in eight. In ve cases (31.25%), the coexistence of endometrioma and mature cystic
teratoma in the same ovary was observed. The mean operation time was signicantly shorter in the
teratoma group than in the complex group (61.02 ± 22.74 vs. 86.31 ± 35.35 min, p = 0.007). The complex
group had more dysmenorrhea (43.8% vs. 7.3%, p = 0.002) and a signicantly higher rate of decrease in
serum anti-Müllerian hormone (AMH) levels (33.06 ± 24.92 vs. 16.31 ± 28.17%, p = 0.048).
Conclusion(s)
The prevalence of coexisting endometriosis and mature cystic ovarian teratoma may be underestimated.
Patients with this rare concurrence may present with worsening dysmenorrhea and damage to ovarian
reserve after surgery may be greater in patients with coexisting endometriosis than in patients with
mature cystic teratoma alone.
Background
Mature cystic ovarian teratomas (MCTs) or dermoid cysts are the most common ovarian tumor in women
of reproductive age and account for about 20% of ovarian tumors [1, 2]. MCTs account for approximately
70% of benign ovarian tumors in women under 30 year of age and 50% of pediatric tumors [3, 4]. They
occur bilaterally in 10–15% of cases [1]. These tumors are usually asymptomatic and are often
discovered incidentally during routine physical or during radiologic examinations [5, 6] The proportion of
asymptomatic tumors has been reported to range from 6–64.5% [7, 8, 9, 10]. In addition, MCTs have a
tendency to grow slowly with an estimated growth rate of 1.67 mm/year [1]. Therefore, recently, expectant
management of MCTs as an alternative to surgical management has been proposed [1, 3].
Page 3/18
Endometriosis is a chronic inammatory condition dened by the presence of endometrial tissue with
glands and stroma outside the uterus [11]. Endometriosis is estimated to affect 10% of women in the
reproductive age group [12]. The incidence of endometriosis in women with dysmenorrhea is
approximately 40–60%, whereas it is up to 20–30% in women with subfertility [11, 13].
Although MCTs and endometriosis are common gynecologic disorders occurring in women of
reproductive age, concomitant MCTs and endometriosis are notably rare and have been reported in few
case reports. However, the author has observed some patients with unusual concomitant MCTs and
endometriosis.
The aim of this study was to determine the incidence of endometriosis in patients with a diagnosis of
MCT who underwent laparoscopy and to clarify further the clinical manifestations of this condition.
Methods
Patients
All patients operated on for MCTs at the Departments of Obstetrics and Gynecology of the Chonbuk
National University Hospital from January 2017 through December 2018 were included in this
retrospective study. This study was approved by the Institutional Review Board of Chonbuk National
University Hospital (File number: 2018-05-018-006). The requirement for obtaining informed consent from
the patients was not applicable owing to the retrospective nature of the study.
The inclusion criteria were as follows: (1) mature cystic ovarian teratoma conrmed by pathology and (2)
endometriosis diagnosed by a pathology specimen and/or a visual conrmation of endometriosis
lesions. The exclusion criteria were as follows: (1) patients with a history of previous adnexal surgery, and
(2) any hormonal treatment, such as oral contraceptives, within six months prior to surgery. All patients
were divided into the following groups: patients with MCTs alone (teratoma group) and patients with
concomitant MCTs and endometriosis (complex group).
Data regarding the patient’s age, parity, body mass index (BMI), preoperative serum cancer antigen (CA)
125 and carbohydrate antigen (CA) 19 − 9 level, hemoglobin (Hb) level, serum anti-Müllerian hormone
(AMH) level, site and size of cyst, stage of endometriosis and pathology reports were retrieved from
operative reports and medical records. Blood samples were preoperatively measured using
radioimmunoassay for CA 125 and CA 19 − 9. The cutoff values for CA 125 and CA 19 − 9 was 35 U/mL.
The Hb concentration was determined both preoperatively and 24 hours after surgery.
The rate of decrease of Hb concentrations was calculated using the following formula:
[(preoperative Hb concentration – postoperative Day 1 Hb concentration)/(preoperative Hb
concentration)] 100(%).
Page 4/18
The serum AMH concentrations were measured preoperatively and one month after the surgery. The
serum AMH level was determined using an enzyme-linked immunoassay kit, AMH Gen II (Beckman
Coulter, USA).
The rate of decrease of serum AMH levels was calculated using the following formula:
[(preoperative serum AMH level – postoperative month 1 AMH level)/(preoperative serum AMH level)]
100(%).
Cyst size was determined by preoperative imaging studies including ultrasonography, computed
tomography (CT), and magnetic resonance imaging (MRI). In the case of bilateral ovarian cysts, the sum
of their largest diameters was dened as the cyst size. The stage of endometriosis was dened according
to the revised American Fertility Society classication [14].
Statistical analysis
R language ver. 3.3.3 (R Foundation for Statistical Computing, Vienna, Austria) and T&F program ver. 3.0
(YooJin BioSoft, Korea) were used for all statistical analyses. Data was expressed as mean ± standard
deviation for continuous variables. The Mann-Whitney U test or Kruskal-Wallis H test were used to test the
difference of continuous clinical measurements between the teratoma group and the complex group
composed of ovarian endometrioma and peritoneal endometriosis. For post hoc analysis, the Bonferroni
Method
was applied to adjust p value. For categorical variables, data was expressed as sample number
and percentage, N (%), and p values were computed using the chi-squared test or Fisher’s exact test.
Results
A total of 71 patients were included, of whom 55 had teratoma (teratoma group) and 16 had a
coexistence of endometriosis and MCTs (complex group). Table 1 presents their demographic and
clinical characteristics, including serum AMH levels and surgery data.
Page 5/18
Table 1
Demographics and clinical characteristics of patients with mature cystic teratoma alone (teratoma
group) and with coexisting mature cystic teratoma and endometriosis (complex group)
Variable Subgroup N(%) Teratoma Complex p value
Sample No (%) 71(100) 55(77.46) 16 (22.54)
Age (years) 71(100) 26.44 ± 6.82 27.38 ± 5.60 0.436
BMI (kg/m2) 71(100) 23.67 ± 5.81 22.74 ± 4.48 0.685
Parity (n) 71(100) 0.758$
0 55(77.5) 41 (74.5) 14 (87.5)
1 6(8.5) 5 (9.1) 1 (6.2)
2 5 (7) 5 (9.1) 0 (0)
3 3(4.2) 2 (3.6) 1 (6.2)
4 1(1.4) 1 (1.8) 0 (0)
5 1(1.4) 1 (1.8) 0 (0)
CA125 (U/mL) 71(100) 11.97 ± 7.30 19.03 ± 16.49 0.066
CA19-9 (U/mL) 71(100) 41.88 ± 92.45 71.51 ± 121.67 0.218
Largest diameter of cyst (cm) 71(100) 5.85 ± 3.23 7.73 ± 3.19 0.020*
Laterality of cyst (n) 71(100) 0.368
Unilateral 63(88.7) 50 (90.9) 13 (81.2)
Multilateral 8(11.3) 5 (9.1) 3 (18.8)
Locularityof cyst (n) 71(100) 0.054
Page 6/18
Variable Subgroup N(%) Teratoma Complex p value
Unilocular 51(71.8) 43 (78.2) 8 (50)
Multilocular 20(28.2) 12 (21.8) 8 (50)
Preop Hb level (g/dl) 71(100) 13.21 ± 0.90 13.14 ± 0.78 0.689
Postop Hb level (g/dl) 71(100) 11.89 ± 0.95 11.58 ± 0.84 0.298
Decrease of Hb level (g/dl) 71(100) 1.31 ± 0.85 1.56 ± 0.64 0.253
Rate of decrease of serum Hblevels (%) 71(100) 9.82 ± 6.30 11.85 ± 4.69 0.186
Operation time (min) 70(100) 61.02 ± 22.74 86.31 ± 35.35 0.007**
Stage of EMS 16(100) NA
I 8 (50) 0 (0) 8 (50)
III 7(43.8) 0 (0) 7 (43.8)
IV 1(6.2) 0 (0) 1 (6.2)
Preop AMH level (ng/mL) 66(100) 5.38 ± 3.80 4.55 ± 4.08 0.209
Postop AMH level (ng/mL) 65(100) 3.97 ± 2.52 3.01 ± 2.92 0.077
Decrease of AMH level(ng/mL) 63(100) 0.99 ± 1.86 1.54 ± 1.82 0.180
Rate of decrease of serumAMH levels (%) 63(100) 16.31 ± 28.17 33.06 ± 24.92 0.048*
Clinical presentation (n) 71(100)
Abdominal pain 12(16.9) 9 (16.4) 3 (18.8) > 0.99#
Dysmenorrhea 11(15.5) 4 (7.3) 7 (43.8) 0.002#**
Incidental nding 29(40.8) 24 (43.6) 5 (31.2) 0.550#
Page 7/18
Variable Subgroup N(%) Teratoma Complex p value
Irregular vaginalbleeding 19(26.8) 18 (32.7) 1 (6.2) 0.074#
Continuous variables are expressed as mean ± SD.
Categorical variables are expressed as sample number and %.
p−values for continuous variables are computed using Mann−Whitney U test (i.e. Wilcoxon rank−sum test).
p−values for categorical variables are computed using Fisher’s exact test, chi−squared test or two sample proportion test.
p−value$: computed using chi−squared test
p−value#: computed using two sample proportion test
N (%): computed in the total sample or subgroups excluding missing data
BMI: body mass index
CA 125: cancer antigen 125
CA 19−9: carbohydrate antigen 19−9
Hb : hemoglobin
AMH: anti−Müllerian hormone
NA: not available
* p <0.05, ** p <0.01
No other parameters concerning age, parity, body mass index, laterality of cyst, and locularity of cyst
differed signicantly between the two groups. Serum CA 125 and CA 19 − 9 values also showed no
signicant differences between the two groups. The diameter of the cyst was signicantly larger in the
complex group than in the teratoma group (p = 0.02). The mean operation time in the teratoma group was
signicantly shorter with a mean of 61.02 ± 22.74 min vs. 86.31 ± 35.35 min in the complex group (p =
0.007). However, there was no signicant difference in intraoperative blood loss between the two groups.
The rate of decrease in serum AMH levels was signicantly higher in the complex group, with a median of
33.06 ± 24.92 vs. 16.31 ± 28.17 for the teratoma group (p = 0.048).
Further, a comparison of the initial clinical presentation in each group during the visit to doctor is shown
in Fig. 1. The majority of patients in the teratoma group were asymptomatic (24 cases, 43.6%) and the
lesions were discovered incidentally during routine ultrasound examination, whereas the most common
Page 8/18
symptom in the complex group was dysmenorrhea (7 cases, 43.8%). Dysmenorrhea was more common
in the complex group than in the teratoma group (43.8% vs. 7.3%, respectively; p = 0.002).
The complex group was divided into two subgroups according to lesion type of endometriosis: ovarian
endometrioma and peritoneal endometriosis. To compare further which pairs of groups were signicantly
different, post hoc comparison analysis was performed among the three groups: teratoma group, ovarian
endometrioma subgroup, and peritoneal endometriosis subgroup (Table 2). Signicant differences in the
largest diameter of cyst (p = 0.047), operation time (p = 0.02), postoperative serum AMH level (p = 0.045)
were found among the three groups. However, the post hoc comparison analysis showed that the
postoperative serum AMH level alone was signicantly lower in the ovarian endometrioma subgroup than
in the teratoma group (p = 0.039). The difference in the rate of decrease in the serum AMH levels among
the three groups was a borderline level of statistical signicance (p = 0.059), but in the post-hoc
comparison analysis, the differences in each subgroups were not statistically signicant although the
difference was the largest between the teratoma group and the ovarian endometrioma subgroup (p =
0.065).
Page 9/18
Table 2
Mean comparison analysis among teratoma group and the complex group (ovarian endometrioma and
peritoneal endometriosis)
Variable Teratoma
(N = 55,
77.5%)
Ovarian
endometrioma
(N = 5, 7%)
Peritoneal
endometriosis
(N = 11,
15.5%)
p
value
p
value
[1]
p
value
[2]
p
value
[3]
Age (years) 26.44 ± 6.82 28.2 ± 5.54 27 ± 5.85 0.659 > 0.99 > 0.99 > 0.99
BMI (kg/m2) 23.67 ± 5.81 24.01 ± 7.12 22.17 ± 2.94 0.885 > 0.99 > 0.99 > 0.99
CA125 (U/mL) 11.97 ± 7.3 22.08 ± 13.42 17.65 ± 18.15 0.120 0.193 0.791 > 0.99
CA19-9(U/mL) 41.88 ± 92.45 112.77 ± 177.63 52.75 ± 91.35 0.262 0.328 > 0.99 0.856
Largestdiameter ofcyst (cm)
5.85 ± 3.23 8.98 ± 3.45 7.16 ± 3.06 0.047* 0.112 0.349 > 0.99
Preop Hb level(g/dl) 13.21 ± 0.9 12.56 ± 0.66 13.41 ± 0.7 0.132 0.210 > 0.99 0.147
Postop Hblevel (g/dl) 11.89 ± 0.95 11.04 ± 0.76 11.83 ± 0.77 0.147 0.153 > 0.99 0.294
Decrease ofHb level (g/dl) 1.31 ± 0.85 1.52 ± 0.54 1.58 ± 0.71 0.515 > 0.99 > 0.99 > 0.99
Rate ofdecrease ofserum Hblevels (%)
9.82 ± 6.3 12.1 ± 4.27 11.73 ± 5.06 0.388 0.821 > 0.99 > 0.99
Operationtime (min) 61.02 ± 22.74 86.8 ± 22.15 86.09 ± 40.97 0.020* 0.089 0.137 > 0.99
Preop AMHlevel (ng/mL) 5.38 ± 3.8 2.75 ± 1.8 5.67 ± 4.79 0.167 0.176 > 0.99 0.480
Postop AMHlevel (ng/mL) 3.97 ± 2.52 1.48 ± 0.94 3.96 ± 3.37 0.045* 0.039* > 0.99 0.245
Decrease ofAMH level(ng/mL)
0.99 ± 1.86 1.27 ± 0.93 1.71 ± 2.26 0.391 0.855 0.995 > 0.99
Rate ofdecrease ofserum AMHlevels (%)
16.31 ± 28.17 43.55 ± 15.29 26.49 ± 28.33 0.059 0.065 > 0.99 0.574
Page 10/18
Variable Teratoma
(N = 55,
77.5%)
Ovarian
endometrioma
(N = 5, 7%)
Peritoneal
endometriosis
(N = 11,
15.5%)
p
value
p
value
[1]
p
value
[2]
p
value
[3]
Variables are expressed as mean ± SD, and p values are computed using Kruskal−Wallis H test
p−values[1]: computed between the teratoma group and the ovarian endometrioma subgroup using a post−hoc analysis algorithm
of Bonferroni
p−values[2]: computed between the teratoma group and the peritoneal endometriosis subgroup using a post−hoc analysis
algorithm of Bonferroni
p−values[3]: computed between the ovarian endometrioma subgroup and the peritoneal endometriosis subgroup using a post−hoc
analysis algorithm of Bonferroni
BMI: body mass index
CA 125: cancer antigen 125
CA 19−9: carbohydrate antigen 19−9
Hb : hemoglobin
AMH: anti−Müllerian hormone
* p <0.05
The individual clinicopatholgic features of the 16 patients with coexisting MCTs and endometriosis are
shown in Table 3. In ve patients, the coexistence of MCTs and ovarian endometrioma in a single ovary
was observed. In case 5 and case 13, the coexistence of MCTs and ovarian endometrioma with histologic
admixture in an ovarian cyst was observed, whereas in the other cases, separate teratomatous and
endometrial lesions in a single ovary were observed. Further, case 2 had a combination of serous
cystadenoma and teratoma, whereas, case 6 had teratoma with coincidental ovarian endometrioma and
serous cystadenoma as a separate pathology.
Page 11/18
Table 3
Summary of the clinicopathologic characteristics of the 16 patients with coexistent endometriosis and
mature cystic ovarian teratoma.
Case
no.
Age
(yr)
CA125
(U/mL)
CA19-
9(U/mL)
Presentation Stage Pathology
1 26 20.1 47.1 Dysmenorrhea I Teratoma, pelvicendometriosis
2 25 12.2 321.79 Dysmenorrhea I Teratoma, pelvicendometriosis,serous cystadenoma
3 26 5.8 26.44 Dysmenorrhea I Teratoma, pelvicendometriosis
4 36 70.2 71.04 Incidentalndings IV Teratoma, pelvicendometriosis
5 27 19.2 52.19 Abdominal pain IV Teratoma, ovarianendometrioma
6 25 24.2 18.17 Abdominal pain III Teratoma, ovarianendometrioma,seous cystadenoma
7 29 12.9 26.44 Dysmenorrhea I Teratoma, pelvicendometriosis
8 22 17.4 12.61 Dysmenorrhea I Teratoma, pelvicendometriosis
9 38 9.2 2.69 Dysmenorrhea II Teratoma, pelvicendometriosis
10 26 19.9 3.98 Dysmenorrhea I Teratoma, pelvicendometriosis
11 19 12.3 28.94 Incidentalndings I Teratoma, pelvicendometriosis
12 25 29.5 429.19 Incidentalndings III Teratoma, ovarianendometrioma
13 38 1 16.8 Incidentalndings III Teratoma, ovarianendometrioma
14 26 36.5 47.49 Incidentalndings III Teratoma, ovarianendometrioma
CA 125: cancer antigen 125
CA 19−9: carbohydrate antigen 19−9
Page 12/18
Case
no.
Age
(yr)
CA125
(U/mL)
CA19-
9(U/mL)
Presentation Stage Pathology
15 29 8.3 24.82 Abdominal pain III Teratoma, pelvicendometriosis
16 21 5.8 14.41 Irregular vaginalbleeding I Teratoma, pelvicendometriosis
CA 125: cancer antigen 125
CA 19−9: carbohydrate antigen 19−9
Discussion
The present study, to the author’s knowledge, is the rst attempt to investigate the incidence of the
coexistence of MCTs and endometriosis and to evaluate the differential clinical characteristics of
patients with this complex condition.
Although MCTs and endometriosis are benign diseases that commonly affect women of reproductive
age, the coexistence of MCTs and endometriosis, especially in a single ovary, is rare [6, 15, 16]. However,
in this study, this coexistence was not rare. Although this study included a relatively small number of
patients, the incidence of coexisting MCTs and endometriosis was 22.54% and its incidence in a single
ovary was 7.04%. Recently, Matalliotaki et al. proposed that endometriosis is linked with an increased risk
of benign gynecological tumor, such as ovarian cyst, adenomyosis and uterine leiomyomas [17]. In that
study, dermoid cysts (1.5%) were observed in women with endometriosis. This data and the present
study’s ndings suggest that coexisting MCTs and endometriosis may be more common than previously
reported.
MCTs are often discovered incidentally in asymptomatic women [1, 10]. Patients with MCTs develop
symptoms such as discomfort or pain when MCTs are complicated by torsion, rupture, and infection [6].
However, various types of pain are associated with endometriosis: dysmenorrhea, deep dyspareunia, and
pelvic pain unrelated to intercourse or menstruation, such as pain during defecation or urinating [18].
Sonographic examination is the initial method for identifying adnexal cystic structures, but MCTs can be
occasionally dicult to distinguish from endometriomas, hemorrhagic cyst, and mucinous cystic
neoplasm based on ultrasonography alone[19], and additional modalities including CT or MRI may be
needed. However, the complexity and rarity of coexisting MCTs and endometriosis make it more dicult
to diagnose. This study demonstrated a high prevalence of coexisting MCTs and endometriosis in those
presenting with dysmenorrhea. The occurrence of dysmenorrhea was more common among women with
this complex condition, whereas most MCTs occurred without clinical symptoms. The diagnosis of
concomitant endometriosis in patients with MCTs rests on a high index of suspicion. Thus, gynecologic
symptoms such as worsening dysmenorrhea may be a diagnostic clue.
Page 13/18
Further, in this study, the operative time was signicantly shorter in patients with MCTs alone than in
patients with coexisting MCTs and endometriosis. In addition, in one patient with a histologic admixture
of MCTs and endometriosis in an ovarian cyst, the procedure was converted to laparotomy because of
dense adhesions and a larger ovarian cyst (exceeding 10 cm in diameter). These observations indicate
that concurrent endometriosis with MCTs makes surgery much more dicult.
The recommended management of MCTs is generally surgical removal because of a large cyst size, risk
of torsion, and concern for occult malignancy. Traditionally, MCTs have been removed by elective surgery
and this procedure accounts for 20–35% of the surgical removal of ovarian tumors [1, 20]. MCTs are the
most common germ cell tumors of the ovary in women of reproductive age, and account for
approximately 70% of benign ovarian neoplasms in women under 30 years of age [21, 22]. The major
concern among these younger women is future fertility. Therefore, the appropriate treatment of MCTs in
children and adolescents remains unclear. A retrospective study by Hoo et al. found that the success rate
of expectant management of MCTs was high and suggested that this approach be considered as a viable
alternative to surgical management [1]. O’Neill et al. suggested that close follow-up without intervention
should be considered to preserve ovarian function and future fertility in children and adolescents with
MCTs [3]. However, endometriosis found in conjunction with MCTs makes justifying the expectant
approach even more challenging. Endometriosis is a common disorder in adult women. Goldstein et al.
reported a 47% prevalence of endometriosis in adolescents undergoing laparoscopy for pelvic pain
[23.24]. Several studies reported a reduced number of retrieved oocytes for in vitro fertilization and
premature ovarian failure after surgery for endometriosis [25.26]. The present study’s results showed that
the rate of decline of serum AMH levels was signicantly higher in patients with coexisting MCTs and
endometriosis than in patients with MCTs alone. The study’s small sample size makes generalizing the
Conclusion
dicult, but this result suggests that surgical cystectomy for this condition in a single ovary
could cause more damage to the ovarian reserve.
The malignant transformation of MCTs is an uncommon complication, with an incidence of 0.17–2% [3,
4]. However, endometriosis is present in about 10–15% of ovarian cancers and is usually associated with
endometrioid carcinoma or clear cell adenocarcinoma [27]. Moreover, Anteby et al. reported that the
recurrence rate of MCTs following cystectomy was 3–4% [28]. Recurrence rates of endometrioma after
surgical excision vary considerably, ranging from 6 percent through 30 percent [29.30]. Consequently,
patients with coexisting MCTs and endometriosis may have an increased risk of malignancy and
recurrence.
Further, a collision tumor is dened as the coexistence of two adjacent, but histologically distinct tumor
components [31]. Collision tumors have been reported in various organs including the esophagus,
stomach, liver, bone, kidney, central nervous system and lung, and so on, but such tumors are relatively
rare in the ovary [32]. In addition, the most common histologic combination of a collision tumor in the
ovary is the coexistence of teratoma and mucinous tumors; therefore a combination of teratoma with
serous cystadenoma is rare [33].
Page 14/18
This study had several limitations. First, not all patients had pathology-conrmed endometriosis. Second,
the reverse case–the presence of MCTs in patients with endometriosis– was not considered. In addition,
the number of patients analyzed was small.
Conclusions
The ndings of this study suggest that the coexistence of MCTs and endometriosis is not as rare as
previously thought. This study also showed that among women with MCT, those with coexisting
endometriosis had marked dysmenorrhea compared to women with MCT alone and that damage to
ovarian reserve after cystectomy in women with coexisting endometriosis may be greater than in women
with MCT alone. These results can not only help categorizing this complex disease, but can also be used
to standardize its treatment. Nevertheless, further prospective studies are required to verify whether the
coexistence of MCTs and endometriosis is indeed not rare.
Declarations
Ethics approval and consent to participate
This study was approved by the Institutional Review Board of Chonbuk National University Hospital (IRB
File No. 2018-05-018-006 ). Due to the retrospective design of the study an informed consent is not
applicable.
Consent for publication
Not applicable
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author
on reasonable request.
Competing interests
The authors declare that they have no competing interests.
Funding
We did not receive any funding for this study.
Authors’ contributions
HC performed data collection, data analysis, and manuscript writing and editing. The author read and
approved the nal manuscript.
Page 15/18
Acknowledgements
Not applicable
Abbreviations
BMI
body mass index
CA 125
cancer antigen 125
CA 19 − 9
carbohydrate antigen 19 − 9
Hb
hemoglobin
AMH
anti-Müllerian hormone
References
1. Hoo WL, Yazbek J, Hollland T, Mavrelos D, Tong EN, Jurkovic D. Expectant management of
ultrasonically diagnosed ovarian dermoid cysts: is it possible to predict outcome? Ultrasound Obstet
Gynecol 2010;36:235-40.
2. Yan L, Li M, Zhang B, Xu X, Xu Z, Han T, et al. Effect of ovarian dermoid cyst excision on ovarian
reserve and response: Insights from in vitro fertilization. Gynecol Minim Invasive Ther 2016;5:161-5.
3. O’Neill KE, Cooper AR. The approach to ovarian dermoids in adolescents and young women. J
Pediatr Adolesc Gynecol 2011;24:176-80.
4. Ayhan A, Bukulmez O, Genc D, Karamursel BS, Ayhan A. Mature cystic teratomas of the ovary: case
series from one institution over 34 years. Eur J Obstet Gynecol Repro Biol. 2000;33:153-7.
5. 5. Stany MP, Hamilton CA. Benign disorders of the ovary. Obstet Gynecol Clin North Am 2008;35:271-
84.
. Chae H, Rheu C. Endometriosis coexisting with mature cystic teratoma in the same ovary and ectopic
pregnancy of left fallopian tube: a rare coexistence. Clin Case Rep 2015;3:315-8.
7. Kim MJ, Kim NY, Lee DY, Yoon BK, Choi D. Clinical characteristics of ovarian teratoma: age-focused
retrospective analysis of 580 cases. Am J Obstet Gynecol 2011;205:32 e1-4.
. Peterson WF, Prevost EC, Edmunds FT, Hundley JM, Morris FK. Benign cystic teratomas of the ovary;
a clinic-statistical study of 1,007 cases with a review of the literature. Am J Obstet Gynecol
1955;70:368-82.
9. Lakkis WG, Martin MC, Gelfand MM. Benign cystic teratoma of the ovary: a 6-year review. Can J Surg
1985;28:444-6.
Page 16/18
10. Comerci JT Jr, Licciardi F, Bergh PA, Gregori C, Breen JL. Mature cystic teratoma: a clinicopathologic
evaluation of 517 cases and review of the literature. Obstet Gynecol 1994;84:22-8.
11. Selcuk I, Bozdag G. Recurrence of endometriosis; risk factors, mechanisms and biomarkers; review of
the literature. J Turk Ger Gynecol Assoc 2013;14:98-103.
12. Chandra A, Rho AM, Jeong K, Yu T, Jeon JH, Park SY, et al. Clinical experience of long-term use of
dienogest after surgery for ovarian endometrioma. Obstet Gynecol Sci 2018;61:111-7.
13. Farquhar C. Endometriosis. BMJ 2007;334:249-53.
14. American Society for Reproductive: Revised American Society for Reproductive Medicine
classication of endometriosis: 1996. Fertil Steril 1997;67:817-21. .
15. van der Merwe JL, Siebert I, van Wyk AC. Rare case of perplexing ovarian endometriosis. Fertil Steril
2010;94:1910.e17-9.
1. Caruso ML, Pirrelli M. A rare association between ovarian endometriosis and bilateral ovarian
teratoma. Case report. Minerva Ginecol 1997;49:341-3.
17. Matalliotaki C, Matalliotakis M, Ieromonachou P, Goulielmos GN, Zervou MI, Laliotis A, et al. Co-
existence of benign gynecological tumors with endometriosis in a group of 1,000 women. Oncol Lett
2018;15:1529-32.
1. Kinkel K, Frei KA, Balleyguier C, Chapron C. Diagnosis of endometriosis with imaging: a review. Eur
Radiol 2006;16:285-98.
19. Patel MD, Feldstein VA, Lipson SD, Chen DC, Filly RA. Cystic teratomas of the ovary: diagnostic value
of sonography. Am J Roentgenol 1998;171:1061-5.
20. Nezhat C, Winer W, Nezhat F. Laparoscopic removal of dermoid cysts. Obstet Gynecol 1989;73:278-
81.
21. Templeman CL, Fallat ME, Lam AM, Perlman SE, Hertweck SP, O’Connor DM. Managing mature cystic
teratomas of the ovary. Obstet Gynecol Surv 2000;55:738-45.
22. Savasi I, Lacy JA, Gerstie JT, Stephens D, Kives S, Allen L. Management of ovarian dermoid cysts in
the pediatric and adolescent population. J Pediatr Adolesc Gynecol 2009;22:360-4.
23. Smorqick N, As-Sanie S, Marsh CA, Smith YR, Quint EH. Advanced stage endometriosis in
adolescents and young women. J Pediatr Adolesc Gynecol 2014;27:320-3.
24. Goldstein DP, De Cholnoky C, Emans SJ. Adolescent endometriosis. J Adolesc Health Care 1980;1:37-
41.
25. Chen Y, Pei H, Chang Y, Chen M, Wang H, Xie H, et al. The impact of endometrioma and laparoscopic
cystectomy on ovarian reserve and the exploration of related factors assessed by serum anti-
Mullerian hormone: a prospective cohort study. J Ovarian Res 2014;7:108.
2. Busacca M, Vignail M. Endometrioma exision and ovarian reserve: a dangerous relation. J Minim
Invasive Gynecol 2009;16:142-8.
27. Takahashi K, Kurioka H, Irikoma M, Ozaki T, Kanasaki H, Miyazaki K. Benign or malignant ovarian
neoplasms and ovarian endometriomas. J Am Assoc Gynecol Laparosc 2001;8:278-84.
Page 17/18
2. Anteby E, Dubuisson J, Samouth N, Shimonovitz S, Ariel I, Hurwitz A. Germ cell tumors of the ovary
arising after dermoid cyst resections: A long term follow-up study. Obstet Gynecol 1994;83:605-8.
29. Busacca M, Marana R, Caruana P, Candiani M, Muzil L, Calia C, et al. Recurrence of ovarian
endometrioma after laparoscopic excision. Am J Obstet Gynecol 1999;180:519-22.
30. Sesti F, Capozzolo T, Pietropolli A, Marziali M, Bollea MR, Piccione E. Recurrence rate of
endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-
operative hormonal suppression treatment or dietary therapy vs. placebo. Eur J Obstet Gynecol
Reprod Biol 2009;147:72-7.
31. Singh AK, Singh M. Collision tumours of ovary: a very rare case series. J Clin Diagn Res 2014;8:FD14-
6.
32. Choudhary S, Adisesha S. Collision tumors of ovary: a rare phenomenon. Int J Case Rep Imag
2012;3:68-70.
33. Bige O, Demir A, Koyuncuoglu M, Secil M, Ulukus C, Saygili qu. Collision tumor: serous
cystadenocarcinoma and dermoid cyst in the same ovary. Arch Gynecol Obstet 2009;279:767-70.
Figures
Page 18/18
Figure 2
Bar plot representing sample distribution of clinical presentation between the teratoma group and the
complex group. Y axis presented as sample number. Sample percentage (%) of each clinical presentation
presented inside each bar.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.